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ABSTRACT 
Background and Purpose: Serum Neurofilaments are markers of axonal injury. We addressed their 
diagnostic and prognostic role in acute ischemic stroke (AIS) and TIA.  
Methods: Nested within a prospective cohort study, we compared serum neurofilament light chain 
levels (sNfL) drawn within 24 hours from symptom onset in patients with AIS or TIA. Patients 
without MRI on admission were excluded. We assessed if sNfL are associated with: (i) clinical 
severity on admission, (ii) diagnosis of AIS vs TIA, (iii) infarct size on admission diffusion weighted 
imaging (MR-DWI), and (iv) functional outcome at 3 months. 
Results: We analyzed 504 patients with AIS and 111 patients with TIA. On admission, higher NIHSS 
scores were associated with higher sNfL: NIHSS<7 (13.1 pg/ml [IQR: 5.3-27.8]), NIHSS 7-15 (IQR: 
16.7 pg/ml [7.4-34.9]), NIHSS>15 (21.0 pg/ml [IQR: 9.3-40.4]) (P=0.01). Compared to AIS, patients 
with TIA had lower sNfL levels (9.0 pg/ml [95%-CI 4.0-19.0] vs. 16.0 pg/ml [95%-CI 7.3-34.4], 
P<0.001), also after adjusting for age and NIHSS (P=0.006). Among patients with AIS, infarct size on 
admission MR-DWI was not associated with sNfL, neither in univariate analysis (P=0.15), nor after 
adjusting for age and NIHSS on admission (P=0.56). Functional outcome three months after stroke 
was not associated with sNfL after adjusting for established predictors.  
Conclusions: In conclusion, among patients admitted within 24 hours of AIS or TIA onset, admission 
sNfL were associated with clinical severity on admission and TIA diagnosis, but not with infarct size 
on MR-DWI acquired on admission or functional outcome at three months. 
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INTRODUCTION 
 
Blood markers of acute brain injury may help in the management of patients with acute 
cerebrovascular events. Blood markers may help discern patients with an acute ischemic stroke (AIS) 
from transient ischemic attack (TIA), serve as surrogate marker of acute infarct size, and improve 
models predicting functional outcome.  
Neurofilaments are 10 nm polypeptide filaments constituting a major component of the axonal 
cytoskeleton. Neurofilaments consist of at least three subunits: light chain (NfL), medium chain 
(NfM), heavy chain (NfH) and of alpha-internexin.(1) After neuro-axonal injury, neurofilaments are 
released into the extracellular space, cerebrospinal fluid and peripheral blood.(1) In peripheral blood, 
reliable detection of the neurofilament light chain samples has become possible only in recent 
years.(2) Serum neurofilament light chain (sNfL) has been shown to be a marker of injury in a 
number of chronic neurological disorders, including multiple sclerosis(3), frontotemporal 
dementia(4), amyotrophic lateral sclerosis,(5) and in some acute neurological disorders such as acute 
spinal injury (6) and traumatic brain injury(7). However, in AIS and TIA, the role of sNfL has not yet 
been investigated in large study populations. In this prospective cohort study, we assessed if sNfL are 
associated with: (i) clinical severity on admission, (ii) diagnosis of AIS vs. TIA, (iii) infarct size on 
admission MR-Diffusion Weighted Imaging (MR-DWI), and (iv) functional outcome at 3 months. A 
control group was included.  
 
PATIENTS AND METHODS 
 
Ethics Statement: This study (ClinicalTrials.gov: NCT00878813) was approved by the Ethics 
Committees. All patients or their welfare guardians provided written informed consent for the 
collection of data, blood samples, and subsequent analyses. 
Study Design, Inclusion and Exclusion Criteria: This is a prospective cohort study nested within 
the CoRisk Study, a multicenter prospective cohort study described previously (CoRisk-Study, 
ClinicalTrials.gov: NCT00878813).(8) In the CoRisk study, we included consecutive patients >18 
years with AIS or TIA within 24 hours of symptom onset, admitted to the emergency department of 
the University Hospital Bern, Basel and Frankfurt a. M. between March 24, 2009 and April 8, 2011.  
Inclusion and Exclusion Criteria: For this nested cohort study, we selected patients admitted to the 
University Hospital Bern, which represent the majority of the CoRisk cohort (934/1085, 86%), with a 
diagnosis of AIS or TIA. AIS was defined as neurological dysfunction lasting >24 hours with an acute 
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lesion on MR-DWI and no acute intracranial bleeding. TIA was defined as neurological dysfunction 
lasting ≤24 hours and caused by focal brain ischemia without an acute lesion on MR-DWI (a modified 
tissue-based definition).(9) To discriminate AIS from TIA, and to reliably assess the size of the acute 
infarct and sNfL, we excluded patients without Magnetic Resonance Imaging (MRI) on admission 
day (n=270). Finally, we excluded patients with symptoms lasting >24 hours but no acute infarct on 
MR-DWI, as they could neither be classified as AIS nor TIA (n=39), as well as patients with 
insufficient serum left to measure sNfL (n=10). 
The control group consisted of volunteers aged between 18-70 years, without any known neurological 
disease. Information on cardiovascular risk factors was not available for the control group. 
Size Estimation of Acute Infarct: All MRI were acquired prior to thrombolysis, if thrombolysis was 
performed. Infarct sizes on MR-DWI were estimated by consensus of two experienced raters unaware 
of the clinical and laboratory findings. Infarct size was estimated by a commonly used semi-
quantitative method validated for acute infarcts.(10) Infarct sizes were categorized into: i) small 
infarct with a volume of <10 cm3, ii) medium infarct of 10–100 cm3, iii) large infarct with a volume of 
more than 100 cm3.  
Functional Outcome: Trained stroke physicians and study nurses assessed functional outcome three 
months after the acute stroke, either during an outpatient visit or with a structured follow-up telephone 
interview. Unfavorable functional outcome was defined as a modified Rankin Scale (mRS) score of 3 
to 6.(11) 
Biomarker Measurement: Blood was drawn in the emergency room upon admission (day 0). To 
study the temporal evolution of sNfL levels, a subset of patients who underwent thrombolysis 
received a second blood sampling after 24 hours (day 1). After centrifugation for 20 minutes at 
3’000g at room temperature, serum (from EDTA tube) was aliquoted. Tubes were frozen locally at –
70°C. sNfL concentrations were measured in duplicate by a previously described and slightly 
modified electrochemiluminescence (ECL) immunoassay.(2) For further detail please see the 
supplementary information.  
Statistics: Discrete variables were expressed as counts (percentages) and continuous variables as 
medians (interquartile range [IQR]). The distribution of raw sNfL levels was skewed. After log 
transformation with base of 10 of sNfL levels, the distribution of raw sNfL levels approximated a 
normal distribution. To compare variables, we used the Fisher’s exact test (for categorical data), the 
Mann-Whitney-U test (for unmatched continuous data) and the Snedecor-Cochran test (for matched 
continuous data, i.e. sNfL levels of day 0 to day 1). To assess the independent association of sNfL 
with dichotomous endpoint (i.e. AIS vs. TIA), we computed multivariate logistic regression models 
adjusted for established predictors.  
Ordinal regression models were used to explore the association between sNfL and ordinal endpoints 
(i.e. NIHSS-categories and infarct size). Linear regression models were used to explore the 
association between two continuous variables (e.g., Log(sNfL) and hours between symptom onset and 
venipuncture). We report odds ratios (OR) along with 95% confidence intervals as measure of 
association and uncertainty, respectively. 
Sensitivity and specificity of sNfL were calculated based on Receiver-Operating-Characteristic 
(ROC)-curve (C-statistics). Testing was two-sided and P values <0.05 were considered to indicate 
statistical significance. Statistics were calculated using Stata Statistical Software: Release 14.2. 
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RESULTS 
We included 504 patients with AIS, 111 with TIA, and 165 volunteers in the control group. Table 1 
details the baseline characteristics including sNfL levels of patients with AIS or TIA. In the control 
group, median age was 48 years (IQR: 38-56), and 110 volunteers were women (67%). The control 
group had lower sNfL levels than patients with AIS or TIA (2.5 pg/ml [IQR: 0.4-5.4] vs. 15.0 pg/ml 
[IQR: 6.1-31.8], Padjusted for age<0.001). On admission of patients with AIS or TIA, higher NIHSS scores 
were associated with higher sNfL NIHSS<7 (IQR: 13.1 pg/ml [5.3-27.8]), NIHSS 7-15 (16.7 pg/ml 
[IQR: 7.4-34.9]), NIHSS>15 (21.0 pg/ml [IQR: 9.3-40.4]) (Pfor trend=0.03, adjusted for age, etiology, 
and time between symptom onset and venipuncture). Compared to AIS, patients with TIA had lower 
sNfL levels also after adjusting for age and NIHSS (P=0.006, Table 1 & 2). However, the association 
magnitude between sNfL and TIA was moderate, with an area under the curve of sNfL of 0.64 (95% 
CI 0.58-0.69, P<0.001), indicating that 36% of patients with TIA will actually have higher sNfL than 
patients with AIS. Among patients with AIS, infarct size on admission MRI-DWI was not associated 
with sNfL, neither in univariate analysis (P=0.15), nor after adjusting for age and NIHSS on 
admission (P=0.56, Table 2).  
Within the first 24 hours of symptom onset, the delay from stroke onset to venipuncture was neither 
associated with sNfL levels in the unadjusted analysis (R-squared=0.00, P=0.67), nor in the analysis 
adjusted for stroke severity on admission (adj. R-squared=0.01, P=0.71), with no difference across the 
three subgroups stratified by infarct size (Pfor interaction=0.47). Among patients with AIS and TIA, sNfL 
were not significantly associated with leucocytes (P=0.23) or CRP (P=0.12). Twenty-four hours after 
admission, 84 patients with AIS undergoing thrombolysis had a second venipuncture to assess sNfL. 
Before thrombolysis, median sNfL levels were 13.7 pg/ml (IQR: 7.0-27.2), 24 hours later 17.1 pg/ml 
(IQR: 9.6-35.3, P=0.06). A statistically significant increase in sNfL from the admission day to the day 
after was seen only in the subgroup with a large infarct size on admission (n=16), whereby sNfL 
increased from 12.9 pg/ml (IQR: 6.9-32.6) to 38.6 pg/ml (IQR: 20.1-112.5, P=0.02) (Figure 2). Any 
increase in sNfL levels from day 0 to 1 (n=51, 61%) had a sensitivity of 81% and a specificity of 44% 
for a large infarct size (Area under the Curve: 0.78, 95%-CI: 0.63-0.92). After adjusting for age and 
NIHSS, patients with the greatest increase in sNfL from day 0 to day 1 (4th vs. 1st quartile of increase) 
had an almost five-fold higher odds of having a larger infarct size on admission MR-DWI (OR=4.72, 
[95%-CI: 1.10-20.30], P=0.04). 
At 3 months, follow-up information was available for 487 out of the 504 patients classified as AIS 
(follow-up rate: 97%). A poor functional outcome was observed in 153 patients (30%). Their baseline 
sNfL levels were more than twice as high as in patients with good functional outcome (26 pg/ml 
[IQR: 13-47] vs. 13 pg/ml [IQR: 6-30], P<0.001). After adjusting for age, NIHSS, and the infarct size 
on MR-DWI, sNfL were not significantly associated with functional outcome at 3 months (Table 2).  
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DISCUSSION 
In this cohort study, patients with AIS or TIA had higher sNfL levels than volunteers without 
neurological diseases. Clinical severity on admission was associated with sNfL levels drawn in the 
first 24 hours of stroke onset. For the diagnosis of TIA versus AIS – i.e. absence vs. presence of an 
infarct on MR-DWI – sNfL levels discriminated moderately. These findings support the concept that 
sNfL mirror axonal damage. Among patients with AIS, infarct size on MR-DWI was not significantly 
associated with sNfL levels, at least on blood drawn on admission. From admission day to the 
following one, patients with large infarcts on MR-DWI had a significant increase in sNfL levels, 
suggesting that sNfL levels peak only after several days. Three-month outcome was not associated, 
after adjusting for established predictors, with sNfL levels drawn on admission.  
Like our study, two prior studies compared patients with AIS to healthy controls, and found higher 
blood Nf levels among AIS patients.(12, 13) Among patients with AIS, two prior studies observed a 
significant association between clinical severity on admission and blood Nf. (12, 14) A study with 18 
AIS patients found no significant association between NIHSS and sNf, a finding likely due statistical 
underpower. (13) In our study, patients with TIA had 1.7-fold lower sNfL compared to patients with 
AIS, while a study on patients with non-traumatic cervical artery dissection found 6.6-fold lower 
sNfL compared to patients with AIS. In the latter study, sNfL were assessed within 30 days from 
symptom onset (14), i.e. later than in our study, in which sNfL were assessed on admission in all 
patients.(14) During the longer time interval, more NfL are released from damaged axons into the 
blood stream, a phenomenon that may explain the greater difference between TIA in AIS seen when 
sNfL are assessed in blood drawn up to 30 days from symptom onset. 
In our study, the lack of association between infarct size on MR-DWI and sNfL levels on admission 
apparently contrasts with a previous cohort study with AIS patients, where sNfH levels did correlate 
with infarct size on MRI, available in 17 patients.(12) However, in our study, the median time interval 
between AIS onset and the first blood sample (2.8 hours) was shorter than in the cited study (2.8 
hours vs. 7–10 days after stroke onset).(12) Again, this observation suggests a delay in the increase of 
sNf levels after AIS, weakening the association between infarct size and sNfL assessed in blood 
drawn as early as 24 hours of symptom onset. Moreover, it is possible that sNfL levels rise faster in 
patients with large, rather small, infarcts. In support of this view, we found a significant sNfL increase 
from day 0 over day 1 only among patients with large infarcts. While we did not have longitudinal 
blood samples after day 1, sNfH reached their peak at week 3 in 80% of the AIS patients in the study 
by Singh et al.(12) Similarly, a significant increase in sNfL over the first 30 days was observed 
among AIS patients due to non-traumatic vertebral or carotid artery dissection.(14) In contrast, over 
the first 6 days of AIS, no significant sNfH increase was observed among 16 patients with AIS, 
although statistical power was likely too low to detect an increase in sNfH over time.(13) Among 27 
patients with acute spinal injury, sNfL increased steadily over the first 7 days.(6) Overall, these 
findings point to a delayed increase of sNfL in serum after AIS or TIA, making sNf unviable as acute 
ischemic markers in the emergency setting despite their alluring pathophysiological pathway. In 
contrast, sNfL seem to be a promising marker for chronic diseases of the central nervous system, like 
multiple sclerosis (15), amyotrophic lateral sclerosis (16), and frontotemporal dementia (4). For 
instance, in multiple sclerosis, sNfL are associated with gadolinium-enhancing lesions, Expanded 
Disability Status Scale assessments, risk of relapses and disability progression.(3)  
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Among AIS patients with poor functional outcome at 3 months, we found higher sNfL on admission, 
but the association was not significant after correction for age, NIHSS and infarct size, similarly to the 
previous study on patients with cervical artery dissection.(14) Another study found that poor 
functional outcome at 6 months was associated with higher sNfH levels drawn 3 weeks after AIS, but 
confounders were not adjusted for.(12) Thus, sNfL do not seem to add prognostic information beyond 
established predictors like NIHSS and infarct size. In contrast, two prior prospective cohort studies 
showed that copeptin levels measured on blood drawn on admission reclassify 11.8% of AIS-patients 
for the prediction of 3-month disability and 37.2% for the prediction of 3-month mortality. The reason 
for the greater prognostic performance of copeptin over sNf may be the faster release of copeptin into 
the blood stream, given that copeptin does not need to cross the blood-brain barrier, since it secreted 
into the blood stream from the posterior pituitary gland. (17) (18)  
The strengths of this work are the large sample size, the inclusion of patients with symptom onset 
within 24 hours along with discrimination of AIS from TIA based on MR-DWI acquired on 
admission. The present study has limitations. First, the number of longitudinal samples in time was 
too small to reliably assess the dynamic of sNfL, and only patients treated with thrombolysis received 
a second venipuncture for sNfL. Thrombolysis may have mitigated axonal damage, and, 
consequently, the rise of sNfL over the first 24 hours since admission. We aimed, however, to 
primarily assess sNfL as blood marker in the emergency situation. Second, measurement of infarct 
size was semi-quantitative, although based on a published and validated method. However, even the 
discrimination ability of sNfL between TIA and AIS – i.e. absence vs. presence of an infarct on MR-
DWI – was moderate, questioning the clinical relevance of sNfL drawn within 24 hours of symptom 
onset. Third, to quantify sNfL, the ECL assay was used instead of the newly developed single-
molecule array (Simoa) method. For serum measurements, however, sNfL were reported to be highly 
correlated between the ECL assay and Simoa (Spearman correlation coefficient=0.86, p<0.001).(2) 
In conclusion, among patients admitted within 24 hours of AIS or TIA onset, sNfL were associated 
with clinical severity on admission, but not with infarct size on MR-DWI acquired on admission or 
functional outcome at three months. The delayed increase of sNfL levels likely makes sNfL unviable 
as acute ischemic marker, at least when measured in blood drawn as early as 24 hours of symptom 
onset. Given the growing interest in the clinical role of sNfL in many neurological diseases, these 
findings bring new patient-oriented evidence on the role of sNfL among patients admitted with acute 
cerebrovascular events.  
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LEGEND TO THE TABLES AND FIGURES 
Table 1: Baseline characteristics 
Table 2: Association between sNfL and Diagnosis, Clinical Severity, Infarct Sizes on MR-DWI and 
Functional Outcome 
 
Figure 1: Serum Neurofilament Light Chain levels on admission of patients with acute ischemic 
stroke are stratified by infarct size on MR-DWI (n=504). The increase in sNfL through infarct size 
groups was not significant. 
Figure 2: Serum Neurofilament Light Chain (sNfL) levels of patients with acute ischemic stroke with 
a large infarct. Change (paired) from the admission day (day 0) to 24 hours later (day 1).  
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Table 1: Patient Characteristics    
 Acute Ischemic 
Stroke 
(n = 504) 
TIA 
 (n = 111) 
P Value 
Demographic data      
Age, median (IQR), y 68 (59-77) 66 (56-75) 0.04 
Women, n (%) 183 (36) 36 (32) 0.51 
Laboratory values, median (IQR)      
Serum NfL (pg/ml) 16 (7-34) 9 (4-19) <0.001 
Time to blood collection (min)* 160 (91-275) 124 (80-250) 0.06 
Medical history, n (%)  
Hypertension 322 (64) 75 (68) 0.51 
Atrial fibrillation 71 (14) 8 (7) 0.06 
Current smoking 105 (21) 21 (19) 0.80 
Diabetes mellitus 74 (15) 16 (14) 0.54 
Dyslipidemia 288 (58) 72 (65) 0.20 
Previous cerebrovascular event 79 (16) 15 (14) 0.66 
Clinical data, median (IQR)  
NIHSS at admission (points) 5 (2-10) 0 (0-2) <0.001 
 NIHSS <7, n (%) 304 (60) 108 (97) 
<0.001  NIHSS 7-15, n (%) 135 (27) 3 (3) 
 NIHSS >15, n (%) 65 (13) 0 (0)
Body Mass Index (kg/m2) 26 (23-28) 26 (24-29) 0.36 
Thrombolysis, n (%) 190 (38) N/A N/A 
Infarct Volume on MR-DWI      
None detected 0 0 111 (100) 
N/A** Small (1–10mm
3) 244 (48) 0 (0)
Medium (10–100mm3) 200 (40) 0 (0)
Large (>100mm3) 60 (12) 0 (0) 
TOAST subtype, n (%)      
Large-vessel disease 82 (16) 16 (14)
<0.001 
Cardioembolic 186 (37) 20 (18)
Small-artery disease 31 (6) 13 (12) 
Multiple causes 45 (9) 13 (12) 
Other known 25 (5) 1 (1)
Undetermined  135 (27) 48 (43)
NfL denotes Neurofilament Light Chain; NIHSS: National Institute of Health Stroke Scale; mRs: 
modified Rankin scale; N/A: not applicable 
*time from stroke onset to venipuncture. 
**By definition, patients with TIA had no ischemic lesion on MR-DWI (tissue based diagnosis). 
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Table 2 Association between sNfL and Diagnosis, Clinical Severity, Infarct Volumes on MR-DWI and 
Functional Outcome 
 
Acute Ischemic Stroke & TIA, Clinical Severity on Admission* 
 OR 95%-CI P Value 
 Univariate OR (95% CI) for Log10 (sNfL) 1.43 1.14 - 1.80 0.002 
 Multivariate** OR (95% CI) for Log10 (sNfL) 1.35 1.04 - 1.77 0.03 
 
Acute Ischemic Stroke. Infarct Volume on MR-DWI 
 OR 95%-CI P Value 
 Univariate OR (95% CI) for Log10 (sNfL) 1.17 0.94 - 1.44 0.15 
 Multivariate✝OR (95% CI) for Log10 (sNfL) 1.08 0.84 - 1.39 0.56 
 
Acute Ischemic Stroke. Unfavorable Functional Outcome at 3 Months 
Number of Events (% of AIS) 153 (30) 
 OR 95%-CI P Value 
 Univariate OR (95% CI) for Log10 (sNfL) 1.66 1.26 - 2.20 <0.001 
 Multivariate ✝✝ OR (95% CI) for Log10 (sNfL) 1.05 0.74 - 1.49 0.80 
 
TIA vs. Acute Ischemic Stroke 
Number of TIA (% of overall cohort) 111 (18)
 OR 95%-CI P Value 
 Univariate OR (95% CI) for Log10 (sNfL) 0.64 0.51 - 0.80 <0.001 
 Multivariate✝
 
OR (95% CI) for Log10 (sNfL) 0.62 0.44 - 0.87 0.006 
 
MR-DWI denotes Magnetic Resonance Diffusion-Weighted Imaging; AIS, acute ischemic stroke; OR, odds 
ratio; CI, confidence interval; TIA, transient ischemic attack indicates odd ratio. *NIHSS-groups: 0-6 points / 7-
15 points / >15 points.  
**Adjusted for age, etiology, and time between stroke onset and venipuncture  
✝Adjusted for age, NIHSS-group (NIHSS 0-6 / 7-15 / >16). 
✝✝ Adjusted for age, NIHSS-group (NIHSS 0-6 / 7-15 / >16), infarct size on admission DW-MRI. 
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